29 November 2023
29 November 2023
With a target of net zero for 2050, pharmaceutical companies need to tackle scope 3 emissions, that make up the majority of their carbon footprint.
A Phase IIb/III trial studying the company’s immunotherapy izokibep, failed to achieve statistical significance for its primary endpoint
The new scheme for 2024–28, renamed the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), with details here, will be implemented in January.
Opening the first day of the CTO Europe conference, experts set their sights on the impact of digital technologies on oncology trials.
Emergent’s Cyfendus was approved by the US Food and Drug Administration (FDA) as a post-exposure prophylactic for anthrax in July.
The companies will work on up to five targets in the cardiovascular field using Avidity's antibody oligonucleotide conjugate (platform technology.
Closing the first day of the CTO Europe conference, a global CRO shares insights on the drug development lifecycle in oncology.
The emergency use listing is based on non-clinical data where the vaccine demonstrated immune responses against variants in SARS-CoV-2.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.
Give your business an edge with our leading industry insights.
